Xeris Biopharma Expands Workforce with 181,500 RSUs to Attract New Talent

Xeris Biopharma Expands Workforce with Strategic Inducement Grants

Xeris Biopharma Holdings, Inc. announces a significant development as it grants restricted stock units (RSUs) totaling 181,500 shares to 19 new employees, effective January 2, 2025. This initiative is part of Xeris' Inducement Equity Plan, aimed at attracting talent not previously associated with the company. The plan adheres to NASDAQ Listing Rules, emphasizing Xeris' commitment to fostering a skilled workforce that can drive innovation and enhance patient outcomes. The RSUs will vest over three years, contingent upon the employees' continued service, reinforcing the company's strategy to retain top talent in the competitive biopharmaceutical sector.

The addition of these new employees aligns with Xeris' growth-oriented approach in the biopharmaceutical industry, where talent acquisition plays a crucial role in advancing research and development initiatives. With a robust portfolio that includes marketed products such as Recorlev®, Gvoke®, and Keveyis®, Xeris is well-positioned to leverage its expanding workforce to enhance its therapeutic offerings. The company’s commitment to patient care and innovative solutions underpins its strategy of addressing unmet medical needs across various therapeutic areas.

Moreover, Xeris Biopharma is actively advancing its development pipeline, which features XP-8121, a Phase 3-ready once-weekly subcutaneous injection of levothyroxine for hypothyroidism. This product, along with several early-stage programs utilizing proprietary technology platforms like XeriSol® and XeriJect®, illustrates the company’s dedication to innovation. By investing in human capital through strategic inducement grants, Xeris not only strengthens its operational capabilities but also positions itself for continued success in bringing innovative therapies to market.

In addition to its workforce expansion, Xeris remains focused on its core mission of enhancing patient outcomes. The company’s ongoing commitment to research and development is complemented by its existing product offerings, which cater to diverse medical needs. As Xeris continues to grow and innovate, it reinforces its standing as a key player in the biopharmaceutical industry.

For more information about Xeris Biopharma and its initiatives, the company encourages stakeholders to visit its official website or connect via social media platforms.